Latest News-Ascentage Pharma Mediaroom_Page

Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Lisaftoclax (APG-2575) in R/R CLL/SLL

SUZHOU, China, and ROCKVILLE, Md., Mar. 14, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-03-15 14:52 1570

Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

SUZHOU, China and ROCKVILLE, Md., March 8, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-03-09 07:47 3400

Ascentage Pharma Presented at the 40th Annual J.P. Morgan Healthcare Conference Reporting Steady Transition Towards a Full-Fledged Biopharma

SUZHOU, China and ROCKVILLE, Md., Jan. 11, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-01-12 10:19 2267

Ascentage Pharma to Present at the J.P. Morgan 40th Annual Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2022-01-06 08:30 7160

ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety

SUZHOU, China, and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-12-14 22:04 2223

ASH 2021 | Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses

SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-12-14 22:04 2189

Ascentage Pharma and Clover Biopharmaceuticals Announce Clinical Collaboration to Evaluate IAP Antagonist, APG-1387, plus the Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, for the Treatment of Peritoneal Carcinomatosis

SUZHOU and CHENGDU, China, and ROCKVILLE, MD., Dec. 9, 2021 /PRNewswire/ -- Ascentage Pharma (6855....

2021-12-09 21:00 2354

Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia

SUZHOU, China and ROCKVILLE, Md., Nov. 30, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-12-01 08:00 1365

Ascentage Pharma Appoints Mr. Yiqing Chen as Chief Financial Officer

SUZHOU, China, and ROCKVILLE, MD., Nov. 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-11-29 19:01 2136

Ascentage Pharma's Olverembatinib Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia

SUZHOU, China, and ROCKVILLE, MD., Nov. 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-11-22 21:24 1795

Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in Metastatic ER+/HER2- Breast Cancer

SUZHOU, China, and ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-11-08 21:47 2185

ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response

SUZHOU, China, and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-11-05 09:05 3193

ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting

SUZHOU, China and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-11-05 08:43 2326

The Journal of Medicinal Chemistry Publishes Study Showing Potential of the Potent EED Inhibitor EEDi-5273 (APG-5918) to Achieve Complete Tumor Regression by Modulating the Epigenetics

SUZHOU, China, and ROCKVILLE, Md., Oct. 18, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-10-18 22:42 2712

Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma

SUZHOU, China, and ROCKVILLE, MD, Sept 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-09-23 07:40 1705

WCLC 2021 | Mini Oral - Ascentage Pharma Announces Latest Data of Its Investigational Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) Combined with Osimertinib in Patients with EGFR TKI-Resistant Non-Small Cell Lung Cancer

SUZHOU, China, and ROCKVILLE, MD., Sept 9, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-09-09 08:26 5401

Ascentage Pharma Announces 2021 Interim Results Highlighting the Potential of Its Core Drug Candidates and Major Breakthroughs in Strategic Collaborations

SUZHOU, China, and ROCKVILLE, Md., Aug. 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glo...

2021-08-24 19:06 3027

Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

SUZHOU, China, and ROCKVILLE, Md., July 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-07-29 07:40 3825

Ascentage Pharma's MDM2-p53 Inhibitor APG-115 (Alrizomadlin) Granted an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma, Marking the Twelfth Obtained by the Company

SUZHOU, China and ROCKVILLE, Md., July 21, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-07-21 18:37 4034

Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma's Drug Compound pelcitoclax

SUZHOU, China, and ROCKVILLE, Md., July 19, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-07-19 18:41 3362